Karthik Koduru, MD
Hematology & Oncology · Quincy, ILNPI 1720241565
Payments from drug & device makers
Across 212 payments — averaging $566.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$79K
- Lilly USA, LLC$24K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Pfizer$3K
- Merck$246
- Novartis$196
- plus $2K from 29 others
Across 1 payment — averaging $7075.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
What the payments were for
- Consulting fees$11,66528%
- Speaking & faculty fees$21,30051%
- Travel & lodging$5,18413%
- Food & beverage$3,1088%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 10 | $78,593 |
| Lilly USA, LLC | 40 | $23,535 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $12,160 |
| Pfizer | 11 | $3,487 |
| Merck | 17 | $246 |
| Novartis | 15 | $196 |
| AstraZeneca(2 entities) | 13 | $184 |
| Amgen | 5 | $181 |
| E.r. Squibb & Sons, L.L.C. | 17 | $178 |
| Johnson & Johnson(2 entities) | 13 | $171 |
| Sanofi | 9 | $137 |
| Bristol Myers Squibb | 6 | $127 |
| Genentech USA, Inc. | 7 | $103 |
| Comsort, Inc | 1 | $100 |
| Eisai Inc. | 4 | $74 |
| Rigel Pharmaceuticals, Inc. | 4 | $60 |
| Clovis Oncology, Inc. | 4 | $54 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Foundation Medicine, Inc. | 1 | $44 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Boehringer Ingelheim | 2 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $27 |
| Array Biopharma Inc | 2 | $26 |
| Taiho Oncology, Inc. | 2 | $25 |
| GSK | 1 | $23 |
| Tesaro, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| EMD Serono, Inc. | 1 | $12 |
| Incyte Corporation | 1 | $12 |
| Verastem, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,991 in reported general payments places this provider in the 70th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Quincy
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
- Reem KarmaliChicago$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.